Last update Dec. 10, 2022
Anticholinergic drug used as spasmolytic for functional gastrointestinal disorders.
At latest update relevant published data on excretion into breast milk were not found.
It acts locally on the intestinal mucosa. Absorption through the intestine is practically absent (Evangelista 2004, Catalogo 2008), with an excretion being almost 100% unmodified in feces that is determinant for the extremely low levels reached in the plasma: <0.02 mg / L (Zhao 2010), which causes the passage through breastmilk in significant amounts must be very unlikely.
Its very low oral bioavailability minimizes the passage into plasma of the infant from ingested breast milk, except in the premature and in the immediate neonatal period in which there may be greater intestinal permeability.
Although antimuscarinics are thought to decrease prolactin production (Müller 1983, Masala 1982), once lactation is established, milk production depends more on the repeated stimulation of suckling than on prolactin levels.
Side effects are mild and very rarely seen.
The literature on this drug is scarce and it is sold in few countries.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM